NCT05207995CompletedPhase 1/2
The Treatment of Patients With Type 1 Diabetes Mellitus With Autologous Tolerogenic Dendritic Cells
A Phase ½ Study to Evaluate the Safety and Feasibility of Autologous Tolerogenic Dendritic Cells in Patients With Type 1 Diabetes Mellitus
Source: ClinicalTrials.gov · Last updated 2 Dec 2025
Brief summary (registry, in English)
The purpose of this study is to determine the safety and tolerability of the administration of tolerogenic dendritic cells in patients with type 1 diabetes mellitus.
- Status (registry)
- Completed
- Phase (registry)
- Phase 1/2
- Study type
- Interventional
- Enrollment
- 32 (actual)
- First submitted
- 29 Nov 2021
- Start date
- Mar 2022
- Primary completion date
- Dec 2023
- Lead sponsor
- Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus
- Diseases
- Type 1 diabetes
- NCT number
- NCT05207995
What you commit to
- Study type: Interventional · Phase 1/2
- Participants enrolled: 32
- From Mar 2022 to the primary completion date, Dec 2023
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- The presence of any malignant tumor within the last 5 years
- Acute or chronic diseases in the stage of decompensation
- Chronic infectious diseases: HIV, viral hepatitis B, C, tuberculosis
- Chronic and protracted mental disorders, all diseases with the presence of the syndrome of dependence on alcohol, drugs and psychoactive substances, any other condition that makes the patient unable to understand the nature, extent and possible consequences of the study or, in the opinion of the researcher, prevents the patient from observing and performing protocol
- Any other medical condition that, in the opinion of the investigator, may be associated with an increased risk to the patient or may affect the outcome or evaluation of the study
Other
- Patients who are pregnant, breastfeeding, or fertile patients who are not using adequate contraceptive methods
- Patients are unable or unwilling to give written informed consent and / or follow research procedures
Who the study is looking for
- Clinical diagnosis of Type 1 Diabetes Mellitus
- The patient can read, understand, follow the examination procedures and complete, if necessary, the required documentation
- Written informed consent
Age in the registry: 18 years to 60 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Healthcare institution "Minsk City Clinical Endocrinology Center" Coordinator of this site? Confirm its status | Minsk | Belarus | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.